Dr. Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD.

With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft-vs-Host-Disease and was awarded the Van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.

Dr. Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research interests were clinical and translational studies on allogeneic hematopoietic stem cell transplantation, with a particular focus on preclinical studies on graft-versus-host disease. He joined Dr. van den Brink’s laboratory to study thymopoiesis reconstitution after thymic injury, particularly after allogeneic hematopoietic stem cell transplantation.
His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.

Doctor Mohamad Mohty is Professor of Haematology, and head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). He also leads a translational research team (INSERM team) at the Saint-Antoine Research Center, Paris, France. He. Over the past 25 years or so, Professor Mohty, an active member of the EBMT, has always been a key figure of the EBMT and in the stem cell transplant and cellular therapy field. He has published over 600 peer-reviewed articles internationally and lectured in more than 70 countries.
In 2021, Professor Mohty has been nominated a “Chevalier de la Légion d’Honneur”, the highest French award, and one of the world’s most widely recognized decorations.

MD, PhD

Professor of Medicine, Immunology and Dermatology at University of Pittsburgh School of Medicine, Pr. Zarour is a Cancer Immunologist with a long-lasting interest in cancer immunotherapies, cancer vaccines and human T cell immunology. His research focuses on immunotherapies of melanoma, T cell responses to melanoma antigens and on the mechanisms of melanoma-induced T cell dysfunction. He has made seminal contributions in the field of human cancer immunology, identifying multiple novel tumor antigen-specific CD4 epitopes, and determining the role of the novel inhibitory receptor pathways Tim-3 and TIGIT in impeding T cell responses to melanoma. Most recently, he has initiated translational studies evaluating the role of the gut microbiome in regulating clinical responses to PD-1 blockade in melanoma, including a first-in-human clinical trial to evaluate the safety and efficacy of fecal microbiota transplant (FMT) obtained from long-term PD-1 responder patients and pembrolizumab in PD-1 refractory melanoma patients. As a co-leader of the of the Cancer Immunology and Immunotherapy Program (CIIP), he will contribute to its mission, and together with basic and clinical investigators, foster the translation of novel laboratory findings into novel immunotherapy of cancers.

Co-Leader of the Melanoma and Skin Cancer SPORE
Co-Leader Cancer Immunology and Immunotherapy Program

Dr. Jenq is currently an assistant professor at MD Anderson Cancer Center, in the Departments of Genomic Medicine and Stem Cell Transplantation. His research aims to improve outcomes for patients undergoing hematopoietic cell transplantation, with a particular focus on the intestinal microbiota and how changes in the composition of intestinal bacterial commensals can impact on clinical outcomes.
MD

Dr. Peled is a medical oncologist at the Memorial Sloan Kettering Cancer Center. Dr Peled specializes in bone marrow transplantation for blood cancers including leukemias, multiple myeloma, myelodysplastic syndrome, and lymphoma.

He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.

His long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.

Franck Carbonnel, MD, PhD, is a professor of Gastroenterology at the Université Paris Saclay since 2008. and the head of the Gastroenterology Department at the University Hospital
of Kremlin Bicêtre (Assistance Publique-Hôpitaux de Paris). He is specialized in inflammatory bowel disease care and research (clinical, epidemiological and translational). He is also
involved in care of patients with enterocolitis due to immune-checkpoint inhibitors and contributed to their description. He recently investigated the role of intestinal microbiota to predict response and intestinal toxicity of immune checkpoint inhibitors.

MD, PhD

Karim Dabbagh, PhD, is Chairman and independent Director since June 2023, succeeding Jean-Marie Lefevre who will continue to serve as a Board member.
Based in the U.S., Karim Dabbagh, president and CEO of Second Genome Inc., renowned for his innovative work in microbiome science and former executive at Pfizer and Roche, brings extensive experience in pharmaceutical development.

PhD in Biochemistry from University College, London
BSc (Hons) in Biotechnology from Imperial College, London

Dorothée Burkel holds a Master's degree from the Institut d'Etudes Politiques in Paris and is an independent director on the board of Directors. She is also Director of Human Resources, Information Systems and Communication and a member of the Executive Committee of PartnerRe. She brings decades of high-level experience in human resources and communication, having participated in the transformation of companies at an international level in the new technology and financial sectors.
She was formerly HR Director EMEA at Google and HR Director France at AOL.

Chief Corporate and People Operations Officer

Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.

Engineering degree Ecole Centrale Paris, MBA from Insead

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world's most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l'Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.

CFO

Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan.

Claude joined MaaT Pharma as an Independent board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.

PharmD, PhD

Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.

Engineering degree from Ecole Centrale Paris

Nadia Kamal, PhD, Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle, has been appointed in June 2023 as independent director and Chair of the ESG committee. Nadia brings a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation.

Doctorate in immuno-analysis and innovation in clinical biology - Sanofi Diagnostics Pasteur / CNRS.
Master's degree in Business Administration from IAE Poitiers.
Artificial Intelligence in Health University Diploma at Université Paris Cité.